AN2 Therapeutics, Inc. (ANTX) Stock Price & Analysis
AN2 Therapeutics, Inc. (ANTX) closed at USD 3.6 on Thursday, October 15, 2026, up 1.69% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 3.54; the Oct 15, 2026 session ranged USD 3.5–3.69 on volume of 295,942 shares. Market capitalization is $135.85M, with a 52-week range of USD 1–7.19 (NMS). Source: Nexqual, retrieved October 16, 2026 at 05:20 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ANTX.md
Key facts (ANTX)
- Analysts: Buy (mean 2.00 on a 1–5 scale) (2 analysts), mean target USD 9 (range 9–9).
- Total return with dividends: 1Y +205.1% vs S&P 500 +18.1%; 5Y -76.6% vs S&P 500 +85.1%.
Analysts (ANTX)
Consensus Buy (mean 2.00 on a 1–5 scale), 2 analysts; mean target USD 9 (low 9, high 9).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-20 | Guggenheim | Initiated | Buy | $9 |
Total return (dividends reinvested) (ANTX)
| 1Y (from 2025-10-16) | 5Y (from 2022-03-21) | |
|---|---|---|
| Total return | +205.1% | -76.6% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +206.3% | -27.2% |
| Volatility (annualized) | 111.2% | 136.3% |
| Max drawdown | -45.6% (Mar 2026→Apr 2026) | -95.3% (Jan 2024→Aug 2024) |
Key Statistics (as of October 16, 2026 at 05:20 UTC)
| Price | USD 3.6 |
|---|---|
| Change | ▲ 1.69% (up) |
| Previous Close | USD 3.54 |
| Open | USD 3.5 |
| Day Range | USD 3.5 – 3.69 |
| 52-Week Range | USD 1 – 7.19 |
| Volume | 295,942 shares |
| Market Cap | $135.85M |
| Exchange | NMS |
Technical Analysis (ANTX)
Nexqual's technical model rates ANTX "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:20 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 24.57 (oversold) |
| vs SMA50 | Below (USD 5.36) |
| MACD | -0.42 (negative) |
Analyst Ratings (ANTX)
Wall Street analysts rate ANTX "Buy" based on 2 analysts, with a mean price target of USD 9 (range USD 9–9), per Nexqual as of October 16, 2026 at 05:20 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 9 |
| High Target | USD 9 |
| Low Target | USD 9 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (ANTX)
| EPS Estimate | USD -0.2 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.18 vs est -0.24 ▲ beat |
| 2026-03-31 | USD -0.29 vs est -0.23 ▼ miss |
| 2025-12-31 | USD -0.29 vs est -0.24 ▼ miss |
| 2025-09-30 | USD -0.31 vs est -0.22 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Financials & Fundamentals (ANTX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -50.12% |
| Current Ratio | 14.32 |
| Total Cash | $78.39M |
| Total Debt | $0 |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Financial Health Score (ANTX)
Nexqual rates AN2 Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:20 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $78M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$31M (TTM) |
| Efficiency | Critical — ROE -50%, ROA -30.8% |
Ownership (ANTX)
| Insider Ownership | +15.99% |
|---|---|
| Institutional Ownership | +76.88% |
| Shares Outstanding | 37.74M |
| Float | 22.29M |
| Short % of Float | +7.84% |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Leadership (ANTX)
AN2 Therapeutics, Inc. is led by Eric E. Easom (age 57), Co-Founder, CEO, President & Chairman of the Board, per Nexqual as of October 16, 2026 at 05:20 UTC.
| Co-Founder, CEO, President & Chairman of the Board | Eric E. Easom (age 57) |
|---|---|
| Co-Founder & Independent Director | Joseph S. Zakrzewski (age 63) |
| CFO, & Principal Financial Officer | Lucy O. Day (age 65) |
| Chief Legal Officer, COO & Corporate Secretary | Joshua M. Eizen (age 46) |
| Vice President of Controller & Principal Accounting Officer | Sarah Williams (age 37) |
Major Backers & Investors (ANTX)
Notable institutional backers of AN2 Therapeutics, Inc. include Vivo Capital, LLC, Commodore Capital Lp, Millennium Management, according to Nexqual as of October 16, 2026 at 05:20 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Vivo Capital, LLC | 8.36% |
| Commodore Capital Lp | 7.77% |
| Millennium Management | 6.14% |
| Spruce Street Capital LP | 4.4% |
| Almitas Capital LLC | 3.89% |
| Adage Capital Partners GP L.L.C. | 2.65% |
| Citadel | 2.52% |
| Boxer Capital Management, LLC | 1.98% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 6.72% |
| Vanguard Group | 6.49% |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:20 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt